BSD Medical second one fourth total revenues lower to $271 naltrexone online.

BSD Medical second one fourth total revenues lower to $271,883 BSD Medical Company ( a respected supplier of medical systems that deal with cancer and benign illnesses using heat therapy, reported financial results because of its second fiscal one fourth ended February 29 today, 2012, including: Money and money equivalents of $14.4 million No debt amount stockholders’ equity of $17 naltrexone online click here .9 million Total revenues of $930,881 for the half a year ended February 29, 2012, in comparison to total revenues of $951,february 28 424 for the half a year ended, 2011 Total revenues of $271,883 for the 90 days ended February 29, 2012, in comparison to total revenues of $444,439 for the 90 days ended February 28, 2011 Net lack of $2,102,february 29 598 for the 90 days ended, 2012, and $3,790,february 29 003 for the half a year ended, 2012 Net cash found in operating actions of $2,631,282 for the half a year ended February 29, 2012 Related StoriesNew findings reveal association between colorectal cancer and melanoma medicine treatmentMD Anderson research reveals why chemotherapy medicines not effective for most pancreatic cancer patientsOvarian cancer sufferers with a brief history of oral contraceptive use have got better outcomes We’ve a solid balance sheet, no debt, and believe we are sufficiently capitalized to keep our advertising and sales and item development efforts, stated Harold Wolcott, President of the ongoing firm.

This technology was employed in the look of the BSD-500 interstitial phased arrays and the BSD-2000 Hyperthermia System to supply uniform preferential heating through the entire central area of a tumor when working with several antennas. The Company used the same advanced synchronous phased array styles in the advancement of the MicroThermX Microwave Ablation Program to supply improved targeting of the ablation therapy sent to the individual . These styles allow the MTX-180 to supply larger and even more uniform zones of ablation throughout a single procedure. The U.S. Meals and Medication Administration offers granted the business a 510 clearance to advertise its MicroThermX Microwave Ablation Program for ablation of smooth tissue..